KR102189166B1 - 할로겐 치환 헤테로환 화합물 - Google Patents

할로겐 치환 헤테로환 화합물 Download PDF

Info

Publication number
KR102189166B1
KR102189166B1 KR1020157019230A KR20157019230A KR102189166B1 KR 102189166 B1 KR102189166 B1 KR 102189166B1 KR 1020157019230 A KR1020157019230 A KR 1020157019230A KR 20157019230 A KR20157019230 A KR 20157019230A KR 102189166 B1 KR102189166 B1 KR 102189166B1
Authority
KR
South Korea
Prior art keywords
biphenyl
amino
carbonyl
thiophen
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157019230A
Other languages
English (en)
Korean (ko)
Other versions
KR20150100756A (ko
Inventor
노리아키 이와세
히로시 니시다
마코토 오쿠도
마사아키 이토
시게유키 고노
마사아키 마토야마
시게루 우시야마
에이지 오카나리
히로후미 마츠나가
겐지 니시카와
도미오 기무라
Original Assignee
우베 고산 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우베 고산 가부시키가이샤 filed Critical 우베 고산 가부시키가이샤
Publication of KR20150100756A publication Critical patent/KR20150100756A/ko
Application granted granted Critical
Publication of KR102189166B1 publication Critical patent/KR102189166B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020157019230A 2012-12-28 2013-12-27 할로겐 치환 헤테로환 화합물 Active KR102189166B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012286425 2012-12-28
JPJP-P-2012-286425 2012-12-28
JP2013097171 2013-05-02
JPJP-P-2013-097171 2013-05-02
PCT/JP2013/085277 WO2014104372A1 (ja) 2012-12-28 2013-12-27 ハロゲン置換へテロ環化合物

Publications (2)

Publication Number Publication Date
KR20150100756A KR20150100756A (ko) 2015-09-02
KR102189166B1 true KR102189166B1 (ko) 2020-12-09

Family

ID=51021433

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157019230A Active KR102189166B1 (ko) 2012-12-28 2013-12-27 할로겐 치환 헤테로환 화합물

Country Status (13)

Country Link
US (2) US10000463B2 (enExample)
EP (2) EP2940013B1 (enExample)
JP (3) JP6176258B2 (enExample)
KR (1) KR102189166B1 (enExample)
CN (2) CN104884447B (enExample)
AU (1) AU2013366898B2 (enExample)
BR (1) BR112015015275B1 (enExample)
CA (1) CA2896701C (enExample)
DK (2) DK3360869T3 (enExample)
ES (2) ES2667798T3 (enExample)
MX (1) MX369801B (enExample)
RU (2) RU2756506C2 (enExample)
WO (1) WO2014104372A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2940013B1 (en) * 2012-12-28 2018-02-21 Ube Industries, Ltd. Halogen-substituted heterocyclic compound
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
JP2014231508A (ja) * 2013-05-02 2014-12-11 宇部興産株式会社 ハロゲン置換へテロ環化合物
WO2015199234A1 (ja) * 2014-06-27 2015-12-30 宇部興産株式会社 ハロゲン置換へテロ環化合物の塩
JPWO2017086430A1 (ja) * 2015-11-20 2018-09-06 宇部興産株式会社 Nashの治療又は予防のための医薬組成物
IL289951B2 (en) * 2019-07-30 2025-10-01 Taisho Pharmaceutical Co Ltd Urea compound as an LPA1 receptor antagonist
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN111909170B (zh) * 2020-09-11 2022-08-12 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件
JP7859068B2 (ja) * 2021-01-28 2026-05-15 大正製薬株式会社 Lpa1受容体を拮抗するウレア化合物を有効成分として含有する医薬
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CA3222642A1 (en) 2022-12-12 2024-06-12 Bmic Llc Downstream uses for briquettes and other forms of powder from asphalt shingle waste
WO2026094986A1 (en) * 2024-11-01 2026-05-07 Hilung Inc. Dry powder pharmaceutical composition for inhalation comprising small molecule lpa1 antagonist and process for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078593A2 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420878T1 (de) * 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
JP4692281B2 (ja) * 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
MX2011003383A (es) 2008-09-29 2011-04-21 Lilly Co Eli Modulador selectivo del receptor de estrogeno para el tratamiento de osteoartritis.
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス,インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
WO2011091167A2 (en) 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
CN103596947A (zh) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
EP2940013B1 (en) * 2012-12-28 2018-02-21 Ube Industries, Ltd. Halogen-substituted heterocyclic compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078593A2 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof

Also Published As

Publication number Publication date
RU2649398C2 (ru) 2018-04-03
US10000463B2 (en) 2018-06-19
RU2756506C2 (ru) 2021-10-01
EP2940013A4 (en) 2016-08-03
MX369801B (es) 2019-11-21
CN104884447A (zh) 2015-09-02
JPWO2014104372A1 (ja) 2017-01-19
CA2896701A1 (en) 2014-07-03
JP6569792B2 (ja) 2019-09-04
MX2015008479A (es) 2015-09-23
RU2015131139A (ru) 2017-02-03
EP2940013A1 (en) 2015-11-04
BR112015015275B1 (pt) 2021-12-14
JP2019014739A (ja) 2019-01-31
WO2014104372A1 (ja) 2014-07-03
BR112015015275A8 (pt) 2019-10-22
US20180258062A1 (en) 2018-09-13
US10597375B2 (en) 2020-03-24
JP6176258B2 (ja) 2017-08-09
AU2013366898A1 (en) 2015-08-13
CN107698555A (zh) 2018-02-16
RU2018109925A3 (enExample) 2020-12-03
CN104884447B (zh) 2017-10-10
EP2940013B1 (en) 2018-02-21
US20150376160A1 (en) 2015-12-31
ES2667798T3 (es) 2018-05-14
CA2896701C (en) 2020-10-06
JP2017214410A (ja) 2017-12-07
KR20150100756A (ko) 2015-09-02
DK3360869T3 (da) 2020-10-12
DK2940013T3 (en) 2018-03-26
JP6414286B2 (ja) 2018-10-31
RU2018109925A (ru) 2019-02-27
EP3360869A1 (en) 2018-08-15
EP3360869B1 (en) 2020-07-29
AU2013366898B2 (en) 2017-06-29
BR112015015275A2 (pt) 2017-07-11
CN107698555B (zh) 2020-05-05
ES2825031T3 (es) 2021-05-14

Similar Documents

Publication Publication Date Title
CN107698555B (zh) 卤素取代杂环化合物
CN108137497B (zh) 新的二环衍生物、其制备方法以及含有它们的药物组合物
AU2010301675B2 (en) Novel phenol derivative
CN106458964B (zh) 卤素取代杂环化合物的盐
CN106478500A (zh) 羧酸取代的(杂)芳环类衍生物及其制备方法和用途
TW202041498A (zh) 抑制pge2/ep4信號傳導的化合物、其製備方法及其在醫藥上的應用
EP3187492A1 (en) Pyrimidinone derivative having autotaxin-inhibitory activity
CN110337433A (zh) 用于调节sgk活性的化合物和药物组合物及其方法
CN111356695B (zh) 新的三环化合物
CN107903208B (zh) 一类联芳吡啶类去泛素化酶抑制剂、其制备方法及应用
CN114685363A (zh) 一类RORγt调节剂、其制备方法及应用
CN119013013A (zh) 用于治疗12-脂加氧酶(12-lox)介导的疾病的组合物和使用方法
KR20260042169A (ko) 12-리폭시게나제(12-lox) 매개 질환의 치료에 사용하기 위한 조성물 및 방법
WO2024104317A1 (zh) 抑制15-pgdh的化合物及其用途
HK1254872A1 (zh) 新的二环衍生物、其制备方法以及含有它们的药物组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150716

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181030

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200221

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20201008

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201203

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20231120

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241119

Start annual number: 5

End annual number: 5